Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer Recurrent
Interventions: RV001V, Placebo; Biological · Other
Lead sponsor: RhoVac APS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more

Conditions: Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions: Givosiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more

Conditions: Primary Sjögren's Syndrome
Interventions: AMG 557/MEDI5872, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 70
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more

Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • National City, California + 14 more

Conditions: Ovarian Cancer
Interventions: Abagovomab, Placebo; Biological
Lead sponsor: Menarini Group; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 22
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 17 more

Conditions: Angioedema
Interventions: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin; Drug
Lead sponsor: Bernstein, Jonathan A., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Alopecia Areata
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 6 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Irvine, California • San Diego, California • Chicago, Illinois + 1 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 652
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo, Background PAH Therapy; Biological · Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more

Conditions: Adult Obesity, Weight Management
Interventions: ECC4703, Placebo, Semaglutide; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Anaheim, California • Los Alamitos, California + 11 more

Conditions: Crohn Disease
Interventions: Sargramostim (Leukine), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 67
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: Elevated Lipoprotein(a), Cardiovascular Disease
Interventions: ISIS 681257, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Perennial Allergic Rhinitis (PAR)
Interventions: LY3650150, Placebo, Standard therapy for INCS; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more

Conditions: Heart Failure, Worsening Heart Failure (WHF)
Interventions: Placebo, R2R01; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 8
States / cities: Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more

Conditions: Coronary Artery Disease
Interventions: MEDI6012, Placebo SC, Placebo IV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more

Conditions: Nasal Polyps
Interventions: Depemokimab (GSK3511294), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more

Conditions: Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions: LY4405094, Placebo, Florbetapir F18, Florbetaben F 18; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more

Conditions: Migraine Headache
Interventions: LY2951742, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more

Conditions: Mild Atopic Asthma
Interventions: BITS7201A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

A Study of Tirzepatide (LY3298176) in Healthy Participants

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Dupilumab in the Treatment of Pediatric Alopecia Areata

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

SAD and MAD Study of FTX-101 in Healthy Male Subjects

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

A Study of LY2951742 in Participants With Migraine

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma